Загрузка...
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge o...
Сохранить в:
| Опубликовано в: : | Cancers (Basel) |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6627706/ https://ncbi.nlm.nih.gov/pubmed/31207938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11060830 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|